Dalteparin Safety in Renal Insufficiency

Safety Profile in Renal Impairment

Prophylactic doses of dalteparin (5000 IU daily) do not show significant bioaccumulation in patients with severe renal insufficiency, according to the National Comprehensive Cancer Network, with a recommended monitoring of anti-Xa levels for therapeutic dosing in severe renal impairment 1, 2, 3
Dalteparin has a more favorable pharmacokinetic profile in renal impairment compared to enoxaparin, as stated by the National Comprehensive Cancer Network, with a lower risk of bioaccumulation 1, 2

Enoxaparin requires dose reduction to 30 mg once daily for prophylaxis and 1 mg/kg once daily for treatment in patients with CrCl <30 mL/min due to 2-3 fold increased bleeding risk, as recommended by the National Comprehensive Cancer Network 2
Tinzaparin should be avoided in elderly patients (≥70 years) with renal insufficiency due to higher mortality rates observed in clinical trials, according to the National Comprehensive Cancer Network 3

For therapeutic dosing in cancer patients with CrCl <30 mL/min, monitoring of anti-Xa levels is recommended to achieve a target range of 0.5-1.5 IU/mL, as stated by the National Comprehensive Cancer Network 1
Consider dose reduction after initial period (e.g., from 200 to 150 units/kg/day after 1 month) for therapeutic dosing, as recommended by the National Comprehensive Cancer Network 4

The National Comprehensive Cancer Network recommends that unlike enoxaparin, which requires dose adjustment in severe renal impairment, dalteparin at prophylactic doses can be used without dose adjustment 5, 6
Enoxaparin requires reduction to 30 mg once daily for prophylaxis in patients with creatinine clearance <30 mL/min due to increased bleeding risk 5, 7
Tinzaparin should be avoided in elderly patients (≥70 years) with renal insufficiency due to higher mortality rates observed in clinical trials 6, 7

For a patient with severe renal impairment, the National Comprehensive Cancer Network suggests that a serum creatinine of 3.3 mg/dL likely corresponds to creatinine clearance <30 mL/min 7
The National Comprehensive Cancer Network recommends considering anti-Xa monitoring only if patient has fluctuating renal function 5
The National Comprehensive Cancer Network suggests considering anti-Xa monitoring only if patient has prolonged course of prophylaxis (>2 weeks) 6
The National Comprehensive Cancer Network recommends considering anti-Xa monitoring only if patient has multiple risk factors for bleeding 6

The National Comprehensive Cancer Network recommends dalteparin for patients with high-risk pulmonary embolism (PESI class 4) and CKD stage 4, due to its superior safety profile compared to other low molecular weight heparins (LMWHs) in patients with severe renal insufficiency 8, 9, 10
Dalteparin does not show significant bioaccumulation at prophylactic doses and can be used at therapeutic doses with appropriate monitoring, unlike enoxaparin which requires mandatory dose reduction in CrCl <30 mL/min 8, 9, 10

The American College of Cardiology recommends starting dalteparin at 200 units/kg subcutaneously once daily for the first month, then reducing to 150 units/kg daily, with mandatory monitoring of anti-Xa levels to maintain a target range of 0.5-1.5 IU/mL 8, 9
Peak anti-Xa levels should be measured 4-6 hours after the 3rd or 4th dose, and anti-Xa levels should be monitored twice weekly during the first month and every 1-2 weeks during extended therapy 8, 10

Enoxaparin should be avoided in patients with CrCl <30 mL/min due to its 2-3 fold increased bleeding risk and required dose reduction to 1 mg/kg once daily 8, 9, 10
Tinzaparin should be avoided in elderly patients with renal insufficiency due to its association with higher mortality compared to unfractionated heparin (UFH) 9, 10

Anti-Xa monitoring schedule should include twice weekly monitoring during the first month and weekly to biweekly monitoring during extended therapy, with adjustments made to maintain target range 8, 10